|Pelvic Inflammatory Disease|
Drawing showing the usual sites of infection in pelvic inflammatory disease
|Classification and external resources|
|NCI||Pelvic inflammatory disease|
|Patient UK||Pelvic inflammatory disease|
Pelvic inflammatory disease or pelvic inflammatory disorder (PID) is an infection of the uterus, fallopian tubes, and possibly ovaries. Often there may be no symptoms. Signs and symptoms, when present may include: lower abdominal pain, vaginal discharge, fever, burning with urination, pain with sex, or irregular bleeding. PID can result in long term complications including: infertility, ectopic pregnancy, and chronic pelvic pain.
Infections by Neisseria gonorrhoeae or Chlamydia trachomatis are present in 75 to 90 percent of cases. Often multiple different bacteria are involved. Without treatment about 10% of those with a chlamydial infections and 40% of those with a gonorrhea infection will develop PID. Risk factors are similar to that of sexually transmitted infections generally and include a high number of sexual partners and drug use. Vaginal douching may also increase the risk. The diagnosis is typically based on the presenting signs and symptoms. It is recommended that the disease be considered in all women of childbearing age who have lower abdominal pain. A definitive diagnosis is made by looking at the fallopian tubes during surgery and seeing pus. Ultrasound may also be useful in diagnosis.
Efforts to prevention the disease include: not having sex or having few sexual partners and using condoms. Screening women at-risk for chlamydial infection followed by treatment decreases the risk of PID. In those in whom the diagnosis is suspected treatment is typically advised. Treating a woman's sexual partners should also occur. In those with mild or moderate symptoms a single injection of the antibiotic ceftriaxone along with 2 weeks of doxycycline and possibly metronidazole by mouth is recommended. For those who do not improve after three days or who have severe disease intravenous antibiotics should be used.
Globally about 106 million cases of chlamydia and 106 million cases of gonorrhea occurred in 2008. The number of cases of PID; however, is not clear. It is estimated to affect about 1.5% of young women yearly. In the United States PID is estimated to affects about one million people yearly. A type of intrauterine device (IUD) known as the dalkon shield lead to increased rates of PID in the 1970s. Current IUDs are not associated with this problem after the first month.
Signs and symptoms
Symptoms in PID range from none to severe. If there are symptoms, then fever, cervical motion tenderness, lower abdominal pain, new or different discharge, painful intercourse, or irregular menstrual bleeding may be noted.
N. gonorrhoea is isolated in 40–60% of women with acute salpingitis. C. trachomatis is estimated to be the cause in about 60% of cases of salpingitis, which may lead to PID. However, not all PID is caused solely by STIs; organisms that are considered normal vaginal flora can be involved, and individual cases of PID can be due to either a single organism or a co-infection of many different species. 10% of women in one study had asymptomatic Chlamydia trachomatis infection and 65% had asymptomatic infection with Neisseria gonorrhoeae. It was noted in one study that 10–40% of untreated women with N. gonorrhoea develop PID and 20–40% of women infected with C. trachomitis developed PID.
Definitive criteria include: histopathologic evidence of endometritis, thickened filled fallopian tubes, or laparoscopic findings. Gram-stain/smear becomes important in identification of rare and possibly more serious organisms. Two thirds of patients with laparoscopic evidence of previous PID were not aware they had PID, however even asymptomatic PID can cause serious harm.
A number of other causes may produce similar symptoms including: appendicitis, ectopic pregnancy, hemorrhagic or ruptured ovarian cysts, twisted ovarian, and endometriosis and gastroenteritis among others.
Pelvic inflammatory disease is more likely to occur when there is a history of pelvic inflammatory disease, recent sexual contact, recent onset of menses, or an IUD (intrauterine device) in place or if the partner has a sexually transmitted infection.
Acute pelvic inflammatory disease is highly unlikely when recent intercourse has not taken place or an IUD is not being used. A sensitive serum pregnancy test should be obtained to rule out ectopic pregnancy. Culdocentesis will differentiate hemoperitoneum (ruptured ectopic pregnancy or hemorrhagic cyst) from pelvic sepsis (salpingitis, ruptured pelvic abscess, or ruptured appendix).
Pelvic and vaginal ultrasounds are helpful in the differential diagnosis of ectopic pregnancy of over six weeks. Laparoscopy is often utilized to diagnose pelvic inflammatory disease, and it is imperative if the diagnosis is not certain or if the patient has not responded to antibiotic therapy after 48 hours.
No single test has adequate sensitivity and specificity to diagnose pelvic inflammatory disease. A large multisite U.S. study found that cervical motion tenderness as a minimum clinical criterion increases the sensitivity of the CDC diagnostic criteria from 83% to 95%. However, even the modified 2002 CDC criteria do not identify women with subclinical disease.
Regular Sexually Transmitted Infection (STI) testing is important for prevention. The risk of contracting pelvic inflammatory disease can be reduced by the following:
- Using barrier methods such as condoms; see human sexual behavior for other listings.
- Seeking medical attention if you are experiencing symptoms of PID.
- Seeking medical attention after learning that a current or former sex partner has, or might have had a sexually transmitted infection.
- Scheduling regular gynecological (pelvic) exams with STI testing to screen for symptomless PID and to discuss sexual history.
- Getting a STI history from your current partner and insisting they be tested and treated before intercourse.
- Diligence in avoiding vaginal activity, particularly intercourse, after the end of a pregnancy (delivery, miscarriage, or abortion) or certain gynecological procedures, to ensure that the cervix closes.
Treatment is usually started empirically because of the serious complications that may result from delayed treatment. Treatment depends on the infectious agent and generally involves the use of antibiotic therapy. If there is no improvement within two to three days, the patient is typically advised to seek further medical attention. Hospitalization sometimes becomes necessary if there are other complications. Treating sexual partners for possible STIs can help in treatment and prevention.
For women with PID of mild to moderate severity, parenteral and oral therapies appear to be efficacious. Clinical experience should guide decisions regarding transition to oral therapy, which usually can be initiated within 24–48 hours of clinical improvement. Typical regimens include cefoxitin or cefotetan plus doxycycline, and clindamycin plus gentamicin. An alternative parenteral regimen is ampicillin/sulbactam plus doxycycline. Another alternative is to use a parenteral regimen with ceftriaxone or cefoxitin plus doxycycline.
Globally about 106 million cases of chlamydia and 106 million cases of gonorrhea occurred in 2008. The number of cases of PID; however, is not clear. It is estimated to affect about 1.5% of young women yearly. In the United States PID is estimated to affects about one million people yearly.
Although the PID infection itself may be cured, effects of the infection may be permanent. This makes early identification by someone who can prescribe appropriate curative treatment very important in the prevention of damage to the reproductive system. Since early gonococcal infection may be asymptomatic, regular screening of individuals at risk for common agents (history of multiple partners, history of any unprotected sex, or people with symptoms) or because of certain procedures (post pelvic operation, postpartum, miscarriage or abortion). Prevention is also very important in maintaining viable reproduction capabilities.
If the initial infection is mostly in the lower tract, after treatment the person may have few difficulties. If the infection is in the fallopian tubes or ovaries, more serious complications are more likely to occur.
PID can cause scarring inside the reproductive organs, which can later cause serious complications, including chronic pelvic pain, infertility, ectopic pregnancy (the leading cause of pregnancy-related deaths in adult females), and other complications of pregnancy. Occasionally, the infection can spread to in the peritoneum causing inflammation and the formation of scar tissue on the external surface of the liver (Fitz-Hugh-Curtis syndrome).
Fertility may be restored in women affected by PID with tuboplastic surgery. In vitro fertilization (IVF) has been used to bypass tubal problems and has become the main treatment for patients who want to become pregnant.
- Salpingitis, any inflammation of the fallopian tubes
- Pelvic peritonitis
- Dalkon Shield — withdrawn from the market in 1975 for PID risk
- Chlamydia infection
- Mitchell, C; Prabhu, M (December 2013). "Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment.". Infectious disease clinics of North America 27 (4): 793–809. PMID 24275271.
- "Pelvic Inflammatory Disease (PID) Clinical Manifestations and Sequelae". cdc.gov. October 2014. Retrieved 21 February 2015.
- World Health Organization (2012). "Global incidence and prevalence of selected curable sexually transmitted infections - 2008". who.int. pp. 2, 19. Retrieved 22 February 2015.
- "Pelvic Inflammatory Disease (PID) Patient Counseling and Education". cdc.gov. October 2014. Retrieved 21 February 2015.
- "Pelvic Inflammatory Disease (PID) Partner Management and Public Health Measures". cdc.gov. October 2014. Retrieved 21 February 2015.
- "2010 STD Treatment Guidelines Pelvic Inflammatory Disease". cdc.gov. August 15, 2014. Retrieved 22 February 2015.
- Eschenbach, D (2008). "Acute Pelvic Inflammatory Disease". Glob. libr. women's med. doi:10.3843/GLOWM.10029. ISSN 1756-2228.
- "Self-Study STD Modules for Clinicians - Pelvic Inflammatory Disease (PID) Next Centers for Disease Control and Prevention Your Online Source for Credible Health Information CDC Home Footer Separator Rectangle Epidemiology". cdc.gov. October 2014. Retrieved 21 February 2015.
- Lauren Nathan; DeCherney, Alan H.; Pernoll, Martin L. (2003). Current obstetric & gynecologic diagnosis & treatment. New York: Lange Medical Books/McGraw-Hill. ISBN 0-8385-1401-4. OCLC 150148652.
- Loscalzo, Joseph; Andreoli, Thomas E.; Cecil, Russell L.; Carpenter, Charles A.; Griggs, Robert C. (2001). Cecil essentials of medicine. Philadelphia: W.B. Saunders. ISBN 0-7216-8179-4. OCLC 43051599.
- Reljic M, Gorisek B (February 1998). "C-reactive protein and the treatment of pelvic inflammatory disease". Int J Gynaecol Obstet 60 (2): 143–50. PMID 9509952.
- Tuboovarian complex by Emily C. Wasco and Gillian Lieberman MD. Beth Israel Deaconess Medical Center. October 17, 2003
- Blenning CE, Muench J, Judkins DZ, Roberts KT (2007). "Clinical inquiries. Which tests are most useful for diagnosing PID?". J Fam Pract 56 (3): 216–20. PMID 17343812.
- Smith KJ, Cook RL, Roberts MS (2007). "Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals". Value Health 10 (5): 358–66. doi:10.1111/j.1524-4733.2007.00189.x. PMID 17888100.
- "Prevention - STD Information from CDC". Center For Disease Control. Retrieved 2015-02-21.
- Walker CK, Wiesenfeld HC (2007). "Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines". Clin. Infect. Dis. 44 (Suppl 3): S111–22. doi:10.1086/511424. PMID 17342664.
- Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37.
- Ness RB, Hillier SL, Kip KE ea. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004;44 (Supp 3):S111–22.
- Smith KJ, Ness RB, Wiesenfeld HC, et al. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis 2007;34:960–6.
- "STD Facts — Pelvic inflammatory disease (PID)". Retrieved 2007-11-23.
- Sutton MY, Sternberg M, Zaidi A, St Louis ME, Markowitz LE (December 2005). "Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985–2001". Sex Transm Dis 32 (12): 778–84. doi:10.1097/01.olq.0000175375.60973.cb. PMID 16314776.
This page uses Creative Commons Licensed content from Wikipedia. A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia.